Clinical Trial Update: A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) [Phase 2]

View source ↗

Summary

Phase 2 study Breakfree-SLE is evaluating CC-97540 (BMS-986353 / Zola-cel), a CD19-targeted NEX-T CAR T cell, in participants with active systemic lupus erythem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• CC-97540 (Zola-cel) (BMS-986353)

Snippet

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Conditions: Lupus Erythematosus, Systemic, Lupus Nephritis | Phase 2 | Status: RECRUITING